Security National Bank of SO Dak Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Security National Bank of SO Dak lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 13,402 shares of the company’s stock after selling 1,006 shares during the quarter. Johnson & Johnson accounts for about 2.3% of Security National Bank of SO Dak’s investment portfolio, making the stock its 10th largest holding. Security National Bank of SO Dak’s holdings in Johnson & Johnson were worth $1,757,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. University of Texas Texas AM Investment Managment Co. bought a new stake in Johnson & Johnson in the 4th quarter worth $31,000. Advocacy Wealth Management Services LLC grew its holdings in Johnson & Johnson by 38.2% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock worth $39,000 after acquiring an additional 83 shares during the last quarter. Lion Street Advisors LLC bought a new stake in Johnson & Johnson in the 1st quarter worth $45,000. Joseph P. Lucia & Associates LLC grew its holdings in Johnson & Johnson by 50.8% in the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after acquiring an additional 126 shares during the last quarter. Finally, Tower View Investment Management & Research LLC bought a new stake in Johnson & Johnson in the 1st quarter worth $55,000. 68.45% of the stock is currently owned by institutional investors.

In other news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were purchased at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the purchase, the director now owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.27% of the company’s stock.

NYSE JNJ opened at $144.56 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. The company has a market capitalization of $380.36 billion, a P/E ratio of 19.12, a P/E/G ratio of 3.14 and a beta of 0.71. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The stock has a 50 day moving average price of $147.76 and a 200-day moving average price of $142.57.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period last year, the company earned $2.10 earnings per share. Johnson & Johnson’s revenue was up 3.3% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.01 per share. The ex-dividend date is Friday, May 22nd. This represents a $4.04 annualized dividend and a dividend yield of 2.79%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.

A number of brokerages have issued reports on JNJ. Barclays raised their price target on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. SVB Leerink lowered their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Finally, Argus reissued a “buy” rating and set a $155.00 price target (down from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $163.47.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What does an outperform rating mean?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).